Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles

Glioblastoma (GBM) is a universally lethal form of brain cancer. The success of novel treatments is hindered by the blood-brain barrier (BBB), which prevents most drugs from penetrating GBM tumors. Sorafenib (SFB), a proapoptotic multikinase inhibitor, has been investigated for the treatment of GBM; however, survival benefit among patients has not improved. Recently, an indocyanine-stabilized nanoparticulate form of SFB (SFB NPs) with improved tumor accumulation was developed in comparison to SFB alone. Herein, the benefit of SFB NPs and focused ultrasound (FUS)-mediated BBB disruption is assessed to enable noninvasive, safe, and reversible BBB permeation for enhanced SFB NPs brain accumulation. Treatment of SFB NPs and FUS yields lower IC50 values (2.7 and 29 mu m in 2D and 3D U87 cell models vs 7.5 and 37.1 mu m for SFB NPs alone). SFB NPs and FUS with microbubbles improve SFB NPs uptake by U87 cells compared to SFB NPs alone (46% increase; p = 0.0123). In vivo, FUS enhances SFB NPs brain accumulation by 2.5-fold compared to the contralateral hemisphere, and 3.6-fold compared to unsonicated brains. In conclusion, SFB NPs are a promising agent for GBM treatment and its therapeutic capacity can be potentially enhanced when combined with FUS-mediated BBB disruption.